To read a factual account of the true history of Pompe DiseaseA rare genetic disease in which the body cannot properly break down glycogen, leading to buildup that damages muscles and can affect breathing and, in some cases, the heart., please visit Pompe Disease—The Real Story.

The AMDA issued a press release regarding the film, Extraordinary Measures. The press release can be found here. In addition,

This information was complied from the information provided on clinicaltrials.gov. To read, please download file by clicking here.

Genzyme would like to provide an update to the US Pompe community about the status of the Alglucosidase AlfaA form of enzyme replacement therapy used to treat Pompe disease by providing a lab-made version of the GAA enzyme. Temporary

Guidelines from Erasmus Medical Centre, Rotterdam, the Netherlands As a guideline we recommend that all patients with Pompe disease are

Genzyme Manufacturing Update Genzyme invites all patients to participate in a forum to discuss recent FDA reports and media attention

Genzyme would like to provide an update to the US Pompe community about the status of the application for Lumizyme™

CRANBURY, N.J., Sept 30, 2009 – – Amicus Therapeutics today announced it plans to initiate a Phase 1 study of

In their second quarter earning statement, Genzyme provided an update on the situation at the Allston manufacturing plant, and the

CAMBRIDGE, Mass. – Genzyme Corporation (Nasdaq: GENZ) announced today that it has submitted the final documentation to address all items